title: Pharmacologic agents for tobacco dependence treatment: 2011 update.
abstract: Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.
authors: Nicotine Dependence Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. hays.taylor@mayo.edu
authors: J Taylor
authors: JT
authors: Hays
authors: David D
authors: DD
authors: McFadden
authors: Jon O
authors: JO
authors: Ebbert
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D012907:Smoking / Q000009:adverse effects*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices / Q000706:statistics & numerical data*; D014029:Tobacco Use Disorder / Q000150:complications / Q000628:therapy*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018722:Nicotinic Agonists